Switzerland

Back to Search

International Partner Search

Innovation & Technology Offer

Respirable microparticles of aminoglycoside antibiotics for lung infections

Country of Origin: Italy
Reference Number: TOIT20170316001
Publication Date: 8 June 2017

Summary

An Italian startup, that works in the pharmaceutical sector, has developed a new technology that produces an antibiotic powder for dry powder inhalers as an innovative treatment of lung infections. 
The startup is looking for pharmaceutical industries that deals with the production of drugs by inhalation, for the industrialization of the innovative technology throughout a license or a joint venture agreements.

Description

An Italian startup, that works in the pharmaceutical sector, has developed a new technology in the life sciences sector for the optimal lung deposition of an inhalation powder.
The startup conduct research in the areas of solid dosage forms (tablets and powder), pulmonary and nasal, with particular reference to pressurized forms or dry powder, liquid forms (eye drops) and transdermal (patches and films).
The technology is a response to the need to release the antibiotic drugs to the pulmonary level of infection. In chronic pulmonary infectious diseases, which require continuous administration of the antibiotic, as happens for example in cystic fibrosis and bronchiectasis, a rapid inhalation administration is more widely accepted by the patient.
The innovative product created is an antibiotic powder obtained by a spray drying process which allows the formation of microparticles with low content of excipients and high breathability. The powder is constituted by particles of very small aerodynamic diameter, low density and favorable shape for aerosolization. These product characteristics reduce the amount of powder to be inhaled at equal dose of antibiotic to be administered, compared to other technologies for inhalation which contain the same active ingredient.
The powder was manufactured accordingly to a patented technology platform. The patent claims the preparation of antibiotic microparticles whose respirability is enhanced by a small amount of sodium stearate deposited on particle surface.
The product addresses the need to increase patient acceptability and consequently the proper intake of the dosages as prescribed in very demanding and delicate therapies. The control of the amount of drug released is achieved thanks to the structure of microparticles and the operation of inhalation device used for dry powders.
The respirable microparticles manufacturing technology is of interest for pharmaceutical industries that deals with the production of drugs by inhalation, both traditional and bio-technology, particularly antibiotics.

The startup is looking for pharmaceutical companies interested to cooperate through license or joint venture agreements for the pre-clinical and clinical studies of efficacy and safety of its innovative technology (with a small investment it could obtain good results).

Advantages and Innovations

- The lung infection therapy conducted by inhalation tackles the pathogen microorganisms at the site of infection at the same time limiting the adverse effects of systemic medication. 
- An inhalation powder facilitates the administration compared to nebulization which requires complex instruments, more time and care efforts.
- Dry powder inhalation technology involves a simple breath through hand able devices which do not need electricity.
- The administration can be carried out everywhere with less drug than nebulization.
- The drug works where it is needed, without affecting healthy organs.

Stage Of Development

Prototype available for demonstration

Stage Of Development Comment

The product got the orphan drug designation from European Medicines Agency (EMA) and Food and Drug Administration (FDA). The scientific advice from EMA is available for the pre-clinical and clinical development.

Requested partner

The startup is looking for industrial partners, that works in the pharmaceutical sector, to launch the pre-clinical and clinical studies of efficacy and safety of its innovative technology, through license and  joint venture agreements.

Contact Profile Owner